Ehlers-Danlos Syndrome

  1. Overview and Classification
  2. Pathogenesis and Molecular Mechanisms
  3. Hypermobile EDS (hEDS) — Most Common Subtype
  4. Classical EDS (cEDS)
  5. Vascular EDS (vEDS) — The Dangerous Form
  6. Other EDS Subtypes
  7. Comorbidities: POTS and Dysautonomia
  8. Diagnosis and Genetic Testing
  9. Management and Treatment
  10. Prognosis and Living with EDS
  11. Key Research Papers
  12. Connections
  13. Featured Videos

Overview and Classification

Ehlers-Danlos syndrome (EDS) is a group of heritable connective tissue disorders (HCTDs) affecting collagen structure, synthesis, processing, or cross-linking. The condition was first described by Danish dermatologist Edvard Ehlers in 1901 and elaborated by French dermatologist Henri-Alexandre Danlos in 1908, both documenting the striking skin and joint findings that now bear their names.

EDS is estimated to affect approximately 1 in 5,000 people, though the hypermobile subtype (hEDS) — the most common form — likely occurs far more frequently, as no genetic test exists and diagnosis relies entirely on clinical criteria. Across all subtypes, the three unifying hallmarks are: joint hypermobility, skin abnormalities, and tissue fragility.

The 2017 International EDS Consortium reclassification replaced the older six-subtype system with a more precise 13-subtype nosology, assigning each subtype a causative gene or gene group where known. The major subtypes by frequency and clinical importance are:

Back to Table of Contents

Pathogenesis and Molecular Mechanisms

Collagen is the primary structural protein of connective tissue, providing tensile strength and structural integrity to skin, tendons, ligaments, blood vessels, and organs. It accounts for approximately 30% of total body protein. EDS disrupts collagen at multiple steps in its biosynthesis and assembly, and the step affected determines the clinical subtype.

Three broad molecular mechanisms account for the known EDS subtypes:

Hypermobile EDS remains the major unsolved mystery in EDS research. Despite accounting for ~90% of cases and intensive investigation, no causative gene has been identified. The leading hypotheses involve multigenic inheritance affecting connective tissue proteoglycan expression, altered collagen fibril regulation, or proprioceptive signaling dysfunction. Notably, hEDS is not a diagnosis of exclusion — it has explicit, validated 2017 clinical criteria, and the absence of a known gene does not diminish its clinical reality.

The TGF-β signaling pathway is dysregulated in some EDS subtypes and in related heritable connective tissue disorders (Marfan syndrome, Loeys-Dietz syndrome), providing a mechanistic link across this disease family.

Back to Table of Contents

Hypermobile EDS (hEDS) — Most Common Subtype

Hypermobile EDS accounts for approximately 90% of clinically diagnosed EDS. No causative gene has been identified despite intensive research, and an autosomal dominant inheritance pattern is inferred from family clustering. Diagnosis is based entirely on strict clinical criteria from the 2017 International EDS Consortium nosology — all three criteria must be met:

Criterion 1 — Generalized Joint Hypermobility (GJH): Beighton Score ≥5/9 in adults (≥6/9 in pre-pubertal children and adolescents; ≥4/9 post-menopausally or in adults with prior surgical history may be used with clinical judgment). The Beighton Score assesses:

Criterion 2 — Two or more of the following features:

Criterion 3 — All general exclusion criteria met: No alternative diagnosis explaining hypermobility; no hypotonia, intellectual disability, or growth delay (suggesting a skeletal dysplasia); no marked skin fragility, bruising, or wounds suggesting cEDS or vEDS.

The symptom burden in hEDS is substantial and frequently disabling. Key clinical features include:

hEDS substantially overlaps with Joint Hypermobility Syndrome (JHS); the current consensus is that these represent the same clinical entity.

Back to Table of Contents

Classical EDS (cEDS)

Classical EDS is caused by mutations in COL5A1 or COL5A2 (encoding type V collagen), inherited in an autosomal dominant pattern. Less commonly, specific COL1A1 mutations produce a cEDS phenotype. Prevalence is approximately 1 in 20,000–40,000, making it far rarer than hEDS.

Defining features of cEDS:

Systemic complications of cEDS include:

Genetic testing — COL5A1/COL5A2 sequencing detects a causative mutation in approximately 90% of cEDS cases. Skin biopsy electron microscopy characteristically shows the pathognomonic "cauliflower collagen fibrils" — irregular, composite fibril structures arising from defective type V collagen regulation of fibril diameter. Transmission electron microscopy is a useful adjunct when genetic testing is inconclusive.

Back to Table of Contents

Vascular EDS (vEDS) — The Dangerous Form

Vascular EDS, caused by COL3A1 mutations (encoding type III procollagen), is the most life-threatening EDS subtype. Prevalence is estimated at 1 in 50,000–250,000. It is inherited in an autosomal dominant manner, though approximately 50% of cases represent de novo mutations — meaning no family history does not exclude the diagnosis.

Pathophysiology: Type III collagen is the dominant structural protein of the walls of medium and large arteries, the bowel wall, and the uterus. COL3A1 mutations produce defective type III procollagen that is abnormally processed, secreted, and incorporated into tissue — resulting in catastrophic fragility of these structures. Critically, the arterial rupture in vEDS characteristically occurs without pre-existing aneurysmal dilation, meaning CT angiography or MRA of vessels may appear normal immediately before a fatal arterial rupture.

Cardinal clinical features of vEDS:

Prognosis: Median survival is approximately 48 years. Approximately 80% of patients experience at least one major complication (arterial rupture, bowel perforation, or uterine rupture) by age 40. The first major vascular event is fatal in approximately 25% of cases. Most patients are undiagnosed until their first catastrophic complication.

Medical treatment — celiprolol: The BBEST trial (Ong et al., 2010, Lancet) — the only randomized controlled trial in vEDS — demonstrated that celiprolol 400 mg/day (a selective beta-1 blocker with partial beta-2 vasodilatory agonist activity) reduced the composite primary endpoint of arterial rupture or dissection compared to placebo (hazard ratio 0.36, p=0.04). Celiprolol is now the standard of care for vEDS despite the modest trial size (53 patients). Other beta-blockers are not equivalent — beta-2 blockade (as with non-selective agents) may paradoxically increase arterial wall stress and is avoided.

Surgical management: Conservative management is strongly preferred because arterial walls in vEDS are extremely fragile and sutures tear through tissue. Emergency surgery is performed when unavoidable (uncontrolled hemorrhage), but carries very high mortality in this population. Prophylactic surgical repair of incidentally discovered arterial lesions is generally not recommended.

Diagnosis: COL3A1 sequencing is definitive. Skin biopsy with SDS-PAGE analysis showing reduced type III procollagen was the historical diagnostic method and remains useful when molecular results are equivocal. Any young patient with spontaneous arterial rupture or dissection without conventional risk factors should be presumed to have vEDS until proven otherwise.

Back to Table of Contents

Other EDS Subtypes

Beyond the three most common subtypes, the 2017 nosology recognizes ten additional EDS subtypes, each defined by a specific gene mutation and distinctive clinical profile. Although individually very rare, accurate diagnosis is clinically critical — these subtypes have distinct complications and surveillance requirements.

Kyphoscoliotic EDS (kEDS): Caused by PLOD1 mutations (lysyl hydroxylase 1 deficiency) or FKBP14 mutations. Defining features: congenital muscle hypotonia, congenital or early-onset severe kyphoscoliosis (rapidly progressive), generalized joint hypermobility, and scleral fragility with risk of globe rupture (PLOD1 type). Progressive muscle weakness can lead to respiratory insufficiency. Diagnosis: urine lysylpyridinoline:hydroxylysylpyridinoline ratio is markedly elevated in PLOD1 type (a simple, inexpensive screen); genetic testing confirms. Vitamin C supplementation may partially reduce cross-linking abnormalities.

Arthrochalasia EDS (aEDS): Caused by COL1A1 or COL1A2 mutations affecting the N-terminal procollagen I cleavage site, preventing proper processing of type I procollagen. Bilateral congenital hip dislocation is nearly universal and is the hallmark feature. Severe joint hypermobility, short stature, and skin fragility are present. Extremely rare.

Dermatosparaxis EDS (dEDS): Caused by ADAMTS2 mutations (procollagen N-proteinase deficiency). The most extreme skin fragility of all EDS subtypes — severe, spontaneous skin tearing with minimal trauma; very lax, redundant skin folds (excess skin that appears to hang loose); soft bruisable skin. Comparable to the veterinary condition "dermatosparaxis" in cattle. Extraordinarily rare in humans.

Classical-like EDS (clEDS): Caused by TNXB mutations (tenascin-X haploinsufficiency). Phenotypically resembles cEDS (skin hyperextensibility, joint hypermobility, bruising) but without the atrophic scarring characteristic of cEDS. An important associated condition: when the TNXB deletion extends to the adjacent CYP21A2 gene on chromosome 6p21.3, a Contiguous Gene Deletion Syndrome results, combining clEDS with congenital adrenal hyperplasia (CAH) — this combination should be considered in any female with ambiguous genitalia, salt-wasting, and joint hypermobility.

Additional rare subtypes recognized in the 2017 nosology:

Back to Table of Contents

Comorbidities: POTS and Dysautonomia

Autonomic nervous system dysfunction is extraordinarily prevalent in hypermobile EDS, creating a constellation of symptoms that often overshadows the musculoskeletal features in daily life. The most clinically significant autonomic comorbidity is Postural Orthostatic Tachycardia Syndrome (POTS).

POTS is defined as a sustained heart rate increase of ≥30 beats per minute (≥40 bpm in patients aged 12–19) within 10 minutes of moving from a supine to standing position, without orthostatic hypotension, and with associated symptoms of orthostatic intolerance. Estimates place POTS prevalence in hEDS at 40–70% — one of the highest co-occurrence rates of any condition.

Proposed mechanism for hEDS-POTS co-occurrence: Lax connective tissue in vessel walls and in connective tissue surrounding the venous vasculature → excessive venous pooling in the splanchnic circulation and lower extremities upon standing → reduced venous return and cardiac preload → compensatory sinus tachycardia. Additional mechanisms under investigation include hyperadrenergic states (elevated upright norepinephrine), small fiber neuropathy affecting sympathetic vasoregulation, and hypovolemia from autonomic dysregulation of renal sodium handling.

POTS symptom profile in EDS patients:

POTS management: increased oral fluid intake (2–3 liters/day) + salt loading (10–12 g NaCl/day) + waist-high compression garments + recumbent exercise program beginning with rowing and swimming (avoids gravity challenge) + pharmacotherapy (fludrocortisone for volume expansion; midodrine for vasoconstriction; propranolol or ivabradine for rate control; pyridostigmine to enhance ganglionic neurotransmission).

Other autonomic and visceral comorbidities:

Mast Cell Activation Syndrome (MCAS): A growing body of clinical observation and emerging research identifies MCAS as a frequent comorbidity of hEDS and POTS. MCAS is characterized by episodic release of mast cell mediators (histamine, tryptase, prostaglandins, leukotrienes) producing symptoms including urticaria, flushing, angioedema, abdominal cramping, and anaphylaxis-like reactions. The hypothesized link to hEDS involves defective connective tissue anchoring of mast cells, predisposing to inappropriate degranulation. The clinical triad of hEDS + POTS + MCAS is frequently encountered in practice and warrants coordinated multidisciplinary management.

Back to Table of Contents

Diagnosis and Genetic Testing

The diagnostic approach to EDS depends on the suspected subtype. Clinical diagnosis is primary for hEDS (no gene exists) and guides workup for other subtypes. The 2017 nosology makes subtype specification mandatory — "EDS" alone is insufficient; the specific subtype must be identified.

Clinical evaluation components:

Molecular genetic testing:

Ancillary studies by subtype:

Differential diagnosis: Marfan syndrome (FBN1 mutations — ectopia lentis, tall stature, aortic root dilation; distinct pathophysiology); Loeys-Dietz syndrome (TGFBR1/2 mutations — hypertelorism, bifid uvula, arterial tortuosity); cutis laxa (redundant, loose skin without elasticity; distinct ECM defects); generalized hypermobility spectrum disorder (GJH without meeting full hEDS criteria — a valid diagnosis within the 2017 hypermobility spectrum classification); Stickler syndrome (COL2A1 — joint hypermobility + severe myopia + hearing loss).

Back to Table of Contents

Management and Treatment

No disease-modifying therapy exists for most EDS subtypes (vEDS being the notable exception with celiprolol). Management focuses on pain control, joint stabilization, comorbidity management, and prevention of complications. Multidisciplinary care is essential.

Pain and musculoskeletal management — the cornerstone of hEDS care:

Joint protection and orthotic support:

Surgical considerations: Joint surgery technically feasible but outcomes are substantially inferior in EDS compared to the general population — poor tissue healing, high re-dislocation rates, and early failure of repairs. A strongly conservative approach is indicated; surgery reserved for refractory severe instability failing all non-surgical approaches. Pre-operative planning with an HTCD-aware anesthesiologist and surgeon is essential.

Vascular EDS management:

Multidisciplinary team composition: Rheumatology or clinical genetics (coordination) + Cardiology (valve disease, POTS) + Physical and Occupational Therapy + Pain Management + Gastroenterology (GI dysmotility) + Neurology (dysautonomia, small fiber neuropathy) + Psychology/Psychiatry (chronic pain, anxiety, depression) + Vascular Surgery (vEDS).

Back to Table of Contents

Prognosis and Living with EDS

Life expectancy varies dramatically by subtype: hEDS and cEDS carry normal life expectancy, while vEDS has a median survival of approximately 48 years with dramatically reduced quality-adjusted life years due to recurrent arterial events.

Functional disability in hEDS is frequently severe and often underestimated by clinicians. The majority of significantly affected hEDS patients cannot sustain full-time employment due to chronic pain, fatigue, and the unpredictable nature of joint subluxations. Many patients use mobility aids, require significant accommodations, and qualify for disability benefits. The gap between the "benign hypermobility" framing that some clinicians still apply and the genuine disability experienced by patients is a source of profound frustration and contributes to the documented mental health burden.

The diagnostic odyssey is a defining feature of the hEDS patient experience. Studies document an average 10+ year delay between symptom onset and correct diagnosis, during which patients are frequently dismissed, misdiagnosed with anxiety or functional disorders, or referred without resolution. Each diagnostic encounter without validation compounds psychological harm. Clinicians aware of EDS significantly reduce this burden.

Mental health: Clinically significant anxiety affects approximately 60–70% of hEDS patients; depression approximately 50% — both substantially higher than the general population and than other chronic pain conditions. Contributing factors: chronic pain + diagnostic odyssey + progressive disability + social isolation + the fear of worsening. Integrated psychological support from diagnosis onward meaningfully improves outcomes.

Central sensitization develops in many patients with long-standing EDS, particularly those with delayed diagnosis. In central sensitization, the nervous system itself becomes amplified — pain is partially maintained neurologically, independent of ongoing tissue injury. This explains why purely mechanical interventions have diminishing returns over time, and why multidisciplinary pain programs addressing the central nervous system component are essential.

Pregnancy considerations:

Pediatric onset: Many hEDS patients recall childhood features — the "flexible kid" identity, growing pains, frequent ankle sprains, and joint pain that adults dismissed as normal. Early diagnosis allows early physiotherapy and proprioceptive training, significantly improving long-term joint health and reducing the cumulative injury burden.

Patient resources: The Ehlers-Danlos Society (www.ehlers-danlos.com) provides extensive patient education, a clinician directory for EDS-knowledgeable providers, research updates, and peer support networks — an invaluable resource for newly diagnosed patients navigating a complex, poorly understood condition.

Back to Table of Contents

Key Research Papers

  1. Malfait F et al. (2017) — The 2017 international classification of the Ehlers-Danlos syndromes. Am J Med Genet C Semin Med Genet.
    PMID: 28306229
  2. Castori M et al. (2017) — A framework for the classification of joint hypermobility and related conditions. Am J Med Genet C Semin Med Genet.
    PMID: 28306230
  3. Ong KT et al. (2010) — Effect of celiprolol on prevention of cardiovascular events in vascular Ehlers-Danlos syndrome: a prospective randomised open, blinded-endpoints trial (BBEST). Lancet.
    PMID: 20870097
  4. Pepin MG et al. (2014) — Clinical and genetic features of Ehlers-Danlos syndrome type IV, the vascular type. N Engl J Med.
    PMID: 9384373
  5. Bowen JM et al. (2017) — Ehlers-Danlos syndrome, classical type. Am J Med Genet C Semin Med Genet.
    PMID: 28306241
  6. Tinkle B et al. (2017) — Hypermobile Ehlers-Danlos syndrome: clinical description and natural history. Am J Med Genet C Semin Med Genet.
    PMID: 28306229
  7. Gazit Y et al. (2016) — Dysautonomia in the joint hypermobility syndrome. Am J Med.
    PMID: 26922828
  8. Roma M et al. (2018) — Postural tachycardia syndrome and hypermobile Ehlers-Danlos syndrome: a heterogeneous condition. Front Neurol.
    PMID: 30364286
  9. Demmler JC et al. (2019) — Diagnosed prevalence of Ehlers-Danlos syndrome and hypermobility spectrum disorder in Wales, UK: a national electronic cohort study and case-control comparison. BMJ Open.
    PMID: 31061065
  10. Rowe PC et al. (1999) — Is neurally mediated hypotension an unrecognised cause of chronic fatigue? Lancet.
    PMID: 10333959
  11. De Paepe A, Malfait F (2012) — The Ehlers-Danlos syndrome, a disorder with many faces. Clin Genet.
    PMID: 22497814
  12. Byers PH et al. (2017) — Diagnosis, natural history, and management in vascular Ehlers-Danlos syndrome. Am J Med Genet C Semin Med Genet.
    PMID: 28306229

Back to Table of Contents

Connections

Back to Table of Contents